Maureen Hillenmeyer, Hexagon Bio CEO
November 8, 2022 08:06 AM EST
Financing
Startups

Scoop: A Soft­Bank-backed biotech rais­es more funds af­ter bag­ging $100M+ for fun­gi min­ing

Kyle LaHucik

Senior Reporter

A biotech min­ing fun­gi to find new drugs for can­cer and in­fec­tious dis­eases is rais­ing an­oth­er round of fi­nanc­ing, End­points News has learned.

Hexa­gon Bio …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

Gilead will close Philadel­phia, Seat­tle of­fices as part of job re­duc­tions

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times